HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$66.66
0.70 (1.06%)
▲
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 05, 2026
4d
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: HAE appears deeply undervalued. Market expects -6.9% annual earnings decline despite 23% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: HAE appears deeply undervalued. Market expects -6.9% annual earnings decline despite 23% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$116.59
Based on 7.3% avg growth
INTRINSIC VALUE TODAY
$72.40
7.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $66.66, which is considered oversold relative to its 30-day fair value range of $69.69 to $82.15. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.1) compared to its historical average (15.1). Remarkably, the market is currently pricing in an annual earnings decline of 6.9% over the next few years. This pessimistic expectation contrasts with the company's recent 22.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is currently testing key support at $64.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $92.00 (+39.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is currently testing key support at $64.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $92.00 (+39.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$69.69 -
$82.15
Company Quality Score
54/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.5% below Wall St target ($92.00)
Fair Price Analysis
30-Day Fair Range
$69.69 -
$82.15
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.77
(5.7%)
Support & Resistance Levels
Support Level
$64.75
Resistance Level
$74.39
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
12.14
Wall Street Target
$92.00
(+39.5%)
Revenue Growth (YoY)
-5.3%
Earnings Growth (YoY)
22.7%
Profit Margin
12.7%
Valuation Discount vs History
-6.9% cheaper
PE vs Historical
12.1 vs 15.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.9%
(market-implied from PE analysis)
1-Year Target
$61.41
(-7%)
2-Year Target
$57.17
(-13%)
3-Year Target
$53.23
(-19%)
3-Yr Target (if PE normalizes)
(PE: 12→15)
$66.23
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 10.6%)
$164.00
(+149%)
Base:
(SPY PE: 12.1, Growth: 10.6%)
$89.25
(+35%)
Bear:
(PE: 10.3, Growth: 10.6%)
$75.86
(+15%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 19.32 | Current EPS (TTM): $3.42
Bull Case
$115.48
(+73%)
Analyst growth 58.9%, PE expands to 21.3
Base Case
$104.99
(+58%)
Market implied 58.9%, PE stable at 19.3
Bear Case
$44.92
(-33%)
Severe decline -20.0%, PE contracts to 16.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.1 to 15.1
Stabilization Target:
$82.07
(+24.4%)
PE Expansion Potential:
+24.4%
Last updated: January 31, 2026 12:05 AM ET
Data refreshes hourly during market hours. Next update: 1:05 AM
Data refreshes hourly during market hours. Next update: 1:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$124 | 59 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$427 | 68 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$85 | 65 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$136 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$374 | 54 HOLD |
Advanced HAE Option Strategies
Professional options setups generated by AI based on today's HAE price and gamma walls.
